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ABSTRACT
PHARMACISTS AS MID-LEVEL HEALTHCARE PROVIDERS AND THE
CLINICAL RESULTS OF A PHARMACIST-LED DIABETES DISEASE
MANAGEMENT PROGRAM
Benjamin Maurice Risner
11/28/2011
Advancements in medical therapy have augmented resources available to
physicians to treat disease and, because of this, spending on prescription drugs
has doubled in the past decade. Increasingly, clinical trials are demonstrating the
benefits of aggressive disease management in reducing morbidity and mortality.
Physicians treating patients with chronic conditions must balance the benefits of
combination drug therapy against the risk of adverse drug events and drug
interactions. For instance, evidence-based practice guidelines in patients with
diabetes and multiple comorbidities require combination therapy in order to
reduce morbidity and mortality. Patients with polymorbidity require the attention
of multiple physicians, further fragmenting patient care and increasing
polypharmacy related issues. Pharmacists are increasingly recognized for
expertise in pharmacodynamics and pharmacokinetics and have been shown to
be beneficial when utilized in patient care. Pharmacists are in a key position to
help physicians manage the balance between optimal disease management and
the risks of polypharmacy.
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CHAPTER 1
INTRODUCTION

Risks and Burdens of Polypharmacy
Abiding by evidence-based standards of care for patients with a chronic
disease often requires that healthcare providers utilize multiple medication
therapy to maximize patient outcomes. However, pursuance of improved patient
outcomes using multiple medication therapy predisposes patients to
polypharmacy. Polypharmacy is generally defined as the ineffective and
inappropriate use of multiple prescription and over the counter (OTC)
medications to the point at which it is detrimental to patient health.[1, 2] The
negative consequences of polypharmacy burden patients, healthcare providers,
and third-party payers alike.
Some common risk factors for polypharmacy include increased age,
multiple prescribers, multiple medication therapy, institutionalization, and
polymorbidity.[1-3] For patients diagnosed with a chronic disease with
complicating and concurrent comorbidities, multiple medication therapy is
necessary for adequate treatment and polypharmacy may be unavoidable.[4] For
example, patients diagnosed with diabetes and common comorbidities such as
hypertension and hyperlipidemia may easily require five or more medications a
day to meet the clinical targets for each of these three conditions.[5]
Paradoxically, the complex multidrug regimes necessary to treat patients with
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polymorbidity may predispose them to complications associated with
polypharmacy. [6-8]
Side effects of polypharmacy include decreased medication compliance,
adverse drug reactions (ADR), increased costs of care, and increased use of
healthcare services (hospitalizations, emergency room visits, etc.). The risk of
polypharmacy associated complications is especially great among patients that
have concurrent comorbidities such as depreSSion, congestive heart failure, and
are being treated by multiple healthcare providers.[1] Further, the inverse
relationship between polypharmacy and medication compliance is routinely found
in patients with diabetes and contributes to poor blood glucose control.[6, 7]
The negative consequences of polypharmacy are disproportionally felt by
the elderly as 37% of individuals over the age of 60 report regular usage of five
or more medications.[9] The elderly are more susceptible to ADRs given their
decreased health literacy and age-related changes in physiology that alter the
concentration and clearance of medications.[8] ADRs cannot only be lifethreatening, they are also a significant cause of hospitalizations and increased
costs.[1 0-12] In addition, declining cognitive function and decreased mobility can
make adherence to medication regimens more difficult.[7]

Effects of Mismanagement on Costs and Utilization
Prescription drug expenditures are expected to escalate in coming years
from $234.1 billion in 2008 to $458 billion in 2019.[13] Research and
development by the pharmaceutical industry have increased the amount of
improved, more effective medical therapy available to treat diseases. In addition,
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marketing campaigns directed toward patients and physicians have increased
the demand for these newer, more costly medications. As such, during 1999 2009 the number of dispensed prescriptions increased 39% along with the
proportion of patients who reported use of multiple prescription medications.[14]
With the increased cost and utilization of prescription medications, both patients
and third-party payers alike stand to benefit from optimized medication therapy.
Medication mismanagement is a substantial contributor to overall
healthcare spending. ADRs, for instance, are a significant cause of
hospitalizations and emergency room visits. Elderly patients are the most likely
patient population to experience severe ADRs with the most common causes of
hospitalization being falls, orthostatic hypotension, and delirium.[8, 15, 16]
Although ADRs can be present at any age, their toll on the elderly population is
greater because of their decreased physiological-reserve. Elderly patients have
decreased muscle mass, increased body fat, decreased renal function, and
decreased hepatic mass altering their ability to metabolize medications. Because
of this, the clinical manifestations related to ADRs are more pronounced among
elderly patients. Additionally, it has been determined that most hospitalizations
involving ADRs are preventable.[16] In fact, hospitalizations often result from
errors such as incorrect dosage, noncompliance, or omission of drug therapy.[15]
The effects of ADRs can also be misdiagnosed by healthcare providers
who then provide patients with additional treatment, further worsening the
patient's polypharmacy. Urinary incontinence, weight loss, cognitive impairment,
malnutrition, constipation, and insomnia are all associated with polypharmacy

3

and are common complaints among elderly patients but are not often recognized
as ADRs. Due to this, patients are routinely offered medications to mitigate their
symptoms, further worsening their polypharmacy.

Pharmacist-led Interventions: The Case for Diabetes
The ineffective use of medication therapy has a serious effect on the most
vulnerable aspects of our population that ripples throughout the entire healthcare
system. Moreover, the preventable nature of most ADRs makes further tolerance
of their subsequent burden to both patients and third-party payers unacceptable.
Effectively combating medication therapy mismanagement will require additional
oversight from pharmacists who are experts in pharmacodynamics and
pharmacokinetics.
With the rising tide of obese and overweight Americans, the prevalence of
diabetes and obesity related comorbidities such as hypertension and heart
disease are expected to increase more than other chronic conditions over the
next decade. Additionally, though diabetes is currently most prevalent in
individuals >65 years old, the great majority of newly diagnosed cases were
among individuals who were 45-64 years of age.[17]
With the average age of diagnosis decreasing, the high number of
comorbidities, and the cost of treatment increasing, diabetes is poised to become
an even greater driver of increased health spending. The decreased amount of
time that physicians are allotted to see patients combined with the more complex
medication regimens needed to achieve clinical targets in patients with diabetes
will further worsen the rates of ADRs and increase costs associated with
4

ineffective medication management.[18, 19] Primary care physicians are also
limited in the amount of problems that they are able to address in the decreased
amount of time they have per patient visit. Primary care physicians' time is
divided between providing direct patient care, reviewing imaging and lab reports,
and addressing phone calls. Though major areas of concern to the patient may
be adequately resolved, it is likely that potential issues with polypharmacy and
ineffective drug therapy will be overlooked.[19]
With the increased burden to patients and third-party payers and the
inability of healthcare providers to ensure that a patient's medication
management is optimized, pharmacists are uniquely pOised as experts in the
field of medication therapy management. Pharmacists' provision of medication
therapy management (MTM) services can increase medication adherence,
improve patient literacy, eliminate duplications in therapy, maximize medication
therapy, and decrease the risk of ADRs. Through optimization of medication
therapy, pharmacists can improve patient clinical outcomes and reduce costs
associated with inadequate patient management.[20]
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CHAPTER 2
PHARMACISTS AS MID-LEVEL PROVIDERS

Though traditionally pharmacists have been employed in various settings
throughout the healthcare industry, their role as service providers has generally
been confined to dispensing and distributing medications. As drug costs and the
number of patients consuming multiple prescription medications increases, the
opportunities for pharmacists to act as mid-level providers (MLP) and provide
medication therapy management (MTM) services is growing. MTM services
provided by pharmacists currently include comprehensive medication reviews,
medication counseling, patient education, collaborative drug therapy
management (CDTM), and disease management programs.
Pharmacist provision of MTM services have been shown to improve
patient outcomes, especially among patients on multiple medications and with
more than one prescriber, such as ICU patients and those with chronic
conditions.[21-23] Patients with these conditions are predisposed to increased
morbidity and mortality associated with polypharmacy. Polypharmacy is generally
defined as the ineffective and inappropriate use of multiple prescription and over
the counter (OTC) medications to the point at which it is detrimental to patient
health.[1, 2] Polypharmacy has been shown to increase the number of adverse
drug events (ADE) and decrease medication compliance, among other things.
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As one may imagine, the direct and indirect healthcare costs associated
with polypharmacy and suboptimal disease management are staggering. In fact,
the healthcare costs for a patient diagnosed with a chronic disease are five times
greater than that of patients who aren't.[23] Many third-party payers including
Medicaid/Medicare, self-insured employers, and private insurance companies,
have begun utilizing pharmacist provided MTM services to reduce their overall
healthcare costs and improve patient health.[24-28]
As healthcare demands continue to increase, the need for pharmacists
who can act as mid-level providers and provide MTM services will grow. Despite
data that demonstrate the benefits of expanding the pharmacist's role in
healthcare to include MTM services, some physicians are understandably
anxious about the increasing profile of non-physician providers in healthcare.[29]
However, as demands for the cost-effective provision of healthcare services
continue to rise, pharmacists will become an invaluable resource for physicians
and payers in optimizing medication management to achieve desired patient
outcomes.[30] The purpose of this manuscript is to advocate for the expanded
role of pharmacists in the clinical setting and explain that their inclusion in
providing care benefits patients and physicians alike.

Background
In the 1950s, pharmacists began to expand their scope of practice beyond
the dispensing and distribution of medication, as pharmacists employed with the
Indian Health Service (IHS) pioneered the concept of clinical pharmacy and
pharmaceutical care. When IHS clinics were first established, many were located
7

in remote areas of the country with limited resources, and an overwhelming need
for medical care necessitated that pharmacists playa larger role in the care of
patients.[31] As federal employees, IHS pharmacists were not limited by
individual state laws regulating their scope of practice.[32] As such, IHS
pharmacists were often utilized to provide comprehensive medication reviews,
screen patients for conditions such as diabetes and hypertension, and to help
coordinate care. The expanded, collaborative relationships that the IHS
pharmacists had with physicians and other healthcare providers also extended to
the inpatient setting as pharmacists would round with physicians to provide
guidance on questions that arose regarding medication.
Given the cultural differences and limited education that were common
among the patient population, collaboration among providers was essential to
ensUre that patients understood their medical condition and remained compliant
with their medications. To help facilitate this, the IHS pharmacists had access to
their patient's full medical records, which allowed the pharmacists to make sure
that patients were receiving optimal drug therapy. Also, because patients often
visit their pharmacist more often than their physician, pharmacists were able to
encourage and facilitate follow-up with the primary care providers.[33, 34]
Aside from the IHS, the Veteran's Health Administration (VHA) has also
utilized pharmacists in expanded clinical roles, working as mid-level providers.
Building on the experiences and success with the IHS, the VHA further expanded
the clinical roles of pharmacists and furthered their incorporation into the primary
care system. The VHA established several specialty clinics where pharmacists,
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with additional training in the treatment of specific conditions, treated patients
under a collaborative drug therapy management (CDTM) agreement with the
patient's prescriber. The CDTM established protocols under which the
pharmacist could initiate, alter, or discontinue therapy to achieve optimal disease
management. The clinics specialized in areas such as diabetes, hypertension,
nephrology, anticoagulation, and HIV. As an example, if a patient at the
anticoagulation clinic was determined to have a sub-therapeutic INR, the
pharmacists had the autonomy to alter the patient's medication to achieve a
therapeutic INR.[35, 36]
In 1996, the city of Asheville, North Carolina, a self-insured employer,
found that chronic diseases such as diabetes were the leading drivers behind its
increasing healthcare costs. Previously, pharmacist-led clinics were provided by
integrated health systems such as the VHA and IHS. The Asheville Project,
however, established pharmacist-led diabetes clinics in community pharmacies
and used incentives such as waived co-pays for diabetes medications and free
testing supplies to ensure patients remained engaged in the program.
The Asheville Project sought participation and advice from local
physicians, dieticians, and area pharmacists in development and implementation
of the pharmacist-led intervention. The pharmacists in the Asheville Project met
with the patients regularly to address blood glucose levels, lipids, and weight
management. The pharmacist would work with the patient to resolve any
medication issues or treatment questions that they had. The pharmacist would
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keep documentation of the visit and send the patient's physician a note detailing
the visit and any areas of concern that they felt needed to be addressed.[25]
Aside from popularity among patients and physicians, the pharmacist-led
intervention in the Asheville Project resulted in consistent improvements in the
patient's HbA 1c and serum lipid values over 14 months of enrollment.[25] As a
result of the intervention, the patient population also had lower healthcare costs
as their clinical improvement led to decreased utilization of costly healthcare
services such as hospitalizations and emergency room visits.
The success of the Asheville Project has since been translated into
pharmacist-led disease management programs being established by other thirdparty payers across the country. For instance, Medicare Part D began providing
MTM services to patients with a high utilization of services as a way to reduce
medication related costs.[37] In addition to Medicare, many state Medicaid
programs have also started to utilize pharmacists' MTM services.[38] For
instance, in 2005 the state of Minnesota passed legislation that would allow
pharmacists to be reimbursed through the state's Medicaid budget for MTM
services provided to patients with chronic illnesses and on multiple medications.
Within the first year of MTM implementation, pharmacists were able to identify
and correct numerous medication errors and the number of diabetic patients
enrolled in the program who had optimal control was greater than the state
average.[28] Similar Medicaid provided MTM programs have been developed in
states like Iowa, Missouri, and North Carolina.[27, 39]
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Unique Among Mid-Level Providers
Mid-level providers are generally classified as non-physician practitioners
(NPP) that provide direct patient care in both the hospital and outpatient setting,
often acting in the role of a "physician extender." Mid-level providers fulfill a
variety of roles in healthcare and include nurse practitioners (NP), certified nurse
midwives (CNM), physician's assistants (PA), and clinical nurse specialists
(CNS). While the training and certification requirements of each mid-level
provider varies, in general, mid-level NPP's have two years of master's level
training, focusing on the provision of basic clinical services such as diagnosing,
examining, and treating patients.[40]
Limitations on the mid-level, NPPs scope of practice vary by state.
However, in most states they are granted prescriptive authority and allowed a
broad range to practice within their ability. The variety of services offered by
NPPs in both the hospital and outpatient setting include physical exams, ordering
and interpretation of diagnostic exams, and minor, noninvasive procedures.
However, mid-level NPPs are reimbursed at a lower rate by Medicare than
physicians because they are confined, by virtue of their training, to providing care
for less complex patients.[40, 41]
Pharmacists differ from other mid-level NPPs in a number of ways
including education, training, and scope of practice. The American Association of
Colleges of Pharmacy (AACP) mandated in 1990 that Doctorate of Pharmacy
(PharmD) would be the first professional degree offered by Schools of
Pharmacy.[42] Pharmacists would still undergo rigorous training regarding the
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appropriate usage, pharmacology, and interactions of drugs as one might expect.
However, pharmacy students are now offered a great deal of clinical training in
patient care and communication as a part of their PharmD program. Also,
pharmacists, unlike other mid-level NPPs, have the option of completing a
residency, becoming certified, and focusing their careers in subspecialty areas
such as nutrition, oncology, HIV, critical care, and others.[42]
Given the extent of their training, pharmacists now have a vast array of
knowledge not only on the mechanisms of various drugs but also on how they
interact with each other and the human body to cure a patient. Because their
training is so extensive, pharmacists possess a unique skill set that is not shared
with other mid-level NPPs or even physicians.[41] Given the potential benefit that
pharmacists can provide to both patients and physicians, their level of
involvement in patient care will only continue to grow.
Pharmacists' role as healthcare providers has largely been defined by the
dispensation and distribution of medications. Increasingly, however, automated
filling systems and pharmacy technicians are dispensing medications under
pharmacist supervision. While this transition has made pharmacies more efficient
and helped control costs, it has left pharmacists seeking a way to expand their
ability to provide services to patients. In addition, now that all pharmacists
entering into practice have obtained their PharmD, many feel that their training
and abilities are being underutilized.
As stated earlier, MTM contains a broad range of cognitive services that
pharmacists provide beyond dispensing and distributing medication. Some of the
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services that pharmacists offer under MTM include chronic disease
management, immunizations, medication surveillance, comprehensive
medication reviews, and pharmacotherapy. These MTM services are being
performed by pharmacists in a variety of both settings including hospitals and
oL!tpatient clinics.[43, 44] Provision of MTM services has shown increased
medication compliance, optimization of therapeutic regimens, and a decrease in
adverse drug events.[44] Patient satisfaction with the care they receive from
pharmacists providing MTM services such as chronic disease management is
generally positive.

Benefit of MTM Services
Polypharmacy is a condition that is prevalent in individuals with chronic
diseases and the elderly. The elderly population consumes almost 30% of the
prescription medications dispensed in the United States and, on average, take
4.5 prescription medications and two over the counter (OTC) medications.[45]
Individuals with multiple chronic conditions such as diabetes, congestive heart
failure, and

capo,

are also likely to be on multiple prescription and OTC

medications. Polypharmacy increases the likelihood that a patient will experience
an AOE or other medication related event requiring a hospitalization and reduces
patients' adherence to medication regimens resulting in suboptimal disease
management.
Given the substantial cost increase that is associated with polypharmacy,
MTM services can be particularly beneficial. Pharmacists are able to perform
comprehensive medication reviews and minimize the possibility of AOEs while
13

simultaneously optimizing the patient's medication management.[46] In addition,
a pharmacist review of a patient medication list can lead to discontinuation of
ineffective or duplicated medication therapy. Given the high cost of prescription
medications and the outcomes that can be associated with ADEs, MTM services
are an essential component to the proper management of patients.

MTM Implementation
In 2003, the Medicare Prescription Improvement and Modernization Act
(MMA) became signed into law, providing increased prescription drug coverage
for individuals enrolled in Medicare. Beginning in 2006, the Center for Medicare
Services (CMS) began requiring providers of Medicare Part D (PDP) to provide
MTM services as a way to save costs, reduce drug interactions and ADEs, and
optimize medication management.[40] The MTM services focused on identifying
and resolving medication related issues and providing comprehensive medication
reviews for patients on multiple Part D medications with multiple chronic
conditions whose drug costs were greater than $4,000. After realizing a
significant savings in drug costs and reductions in medication related errors,
CMS has recently recommended an expansion of their MTM services and has
reduced the cost threshold for eligible patients to $3,000.[40]
Though MTM services have been shown to produce better patient
outcomes and reduce costs, many third-party payers are still not covering these
services. In addition, pharmacists cite an inadequate representation of MTM
services in the current medical coding system as a Significant barrier to obtaining
payment for their services.[47, 48] Also, many third-party payers are not fully
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recognizing MTM services as separate from dispensing services and, because of
this, pharmacists are unable to bill for their services. Pharmacists are also not
recognized by third-party payers as healthcare providers in the same way that
NP, PA, and CPSs are.[48] Because of this, pharmacists are often not able to
bill directly for their services and instead must bill MTM services as incidental to
physician services.[40]
Up until recently, MTM services provided by pharmacists were rare
outside of large, academic settings. Pharmacists working in community-based
retail pharmacies still spend a great deal of their time dispensing medications to
patients. In order to fully implement MTM services, pharmacies would have to
invest more resources into hiring pharmacists and pharmacy technicians.
Pharmacists would also have to find a way to document and bill for their services
and establish a greater amount of communication among physicians in their
area.[49] Currently, with many different health information technology (HIT)
systems being utilized across the country there is no standardized billing and
documentation system which further hinders pharmacists' ability to provide MTM
services.
In order for patients, providers, and payers to receive the greatest amount
of benefit from MTM services, there must be cooperation and collaboration
among all of a patient's healthcare providers. Most successful MTM
implementation has occurred in environments that are conducive to collaboration
among the different healthcare providers and integration of healthcare services.
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Most payers find it necessary to include incentives for patients to remain
engaged with their pharmacist.[28] While it is true that most individuals visit their
pharmacist more than their physician, some pharmacists have complained of
trouble getting patients to follow up after an initial visit. However, financial
incentives such as waived copayments for medications can entice patients to
remain engaged.[50]

MTM Future
Included in the Affordable Care Act (ACA) was a provision for the
development of Accountable Care Organizations (ACO) as a new
comprehensive, patient-centered method delivering patient care that rewards
healthcare providers for the quality of the care they provide. ACOs are
accountable to patients and payers for the cost, quality, and efficiency of the care
that they provide.[51] Since the current fee for service method of paying
healthcare increases utilization without increasing quality, it is likely that a
capitation system of payment will be adopted with provisions for shared
savings.[52] The capitation method of payment provides a lump sum for
healthcare services whether patients utilize services or not. Patients with chronic
diseases who have been enrolled in MTM services have shown a decrease in the
number of ER visits and hospitalizations. Taking the highest risk individuals
enrolled in a health plan and enrolling them in a pharmacist-led MTM service
chronic disease management is a proven method of reducing costs and
improving patient outcomes.[52]
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Pharmacists can also figure prominently in Patient Centered Medical
Homes (PCMH). PCMH is a practice model that places the primary care
physician as the leader of a patient's healthcare team.[53] Aside from the PCMH
serving as a patient's gateway into the healthcare system, it will also provide
patients with disease management and other services that are not currently
offered in most community primary care offices. Having access to a patient's full
medical record, pharmacists will be able to collaborate directly with physicians in
the PCMH to maximize patient outcomes.[46] In addition, given the likelihood that
capitation and shared savings will become the preferred form of payment for
patient care in the future, pharmacist provision of MTM services will be essential
to control costs and improve patient outcomes.[54]
From the data presented, it can be clearly seen that pharmacists as midlevel providers of MTM services have the potential to benefit patients, payers,
and providers. Chronic disease management programs that are administered by
pharmacists have been shown to significantly reduce costs to third-party payers.
Aside from the savings realized immediately by payers, it is hoped that better
management of patients diagnosed with diabetes, for instance, will produce longterm cost savings by reducing complications that result from poorly managed
blood glucose levels such as renal failure.
Further recognition of pharmacists as mid-level providers will require a
greater amount of understanding by physicians and payers as to the benefits of
providing MTM services.[37] In addition, physicians and other providers are
currently paid under a fee-for-service arrangement whereby they are paid more
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for additional services than they provide. Until healthcare providers are provided
an incentive to maximize preventative services and emphasis well ness among
their patients, MTM services will remain underutilized by the healthcare
community.
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CHAPTER 3
CLINICAL RESULTS OF A PHARMACIST-LED DIABETES DISEASE
MANAGEMENT PROGRAM

The impact of chronic diseases on healthcare costs has become an
increasingly important topic. Indeed, the impact of only five or six chronic disease
including diabetes, hypertension, cardiovascular disease (CVD), asthma, chronic
obstructive pulmonary disease (COPD), and musculoskeletal disease account for
75% of the annual health costs in the U.S.[55] Medical advances over the last
half of the twentieth century have provided an abundance of new opportunities to
better treat and manage disease. These advances have not only improved the
quality of life for many people but have also increased the life expectancy for
individuals suffering from chronic diseases. However, the rising life expectancy
coupled with the advanced medical technology required for long-term care of
patients diagnosed with a chronic disease has led to an exponential growth in the
cost of healthcare.[55, 56] The increased cost of healthcare provides a
significant barrier to those seeking medical treatment while also hampering
economic growth and contributing to inflation nationwide.[56] Moreover, a recent
survey of CEOs revealed that employee healthcare places the greatest cost
pressure on American businesses.[57]
Diabetes, primarily type II diabetes, stands out as a particularly significant
driver for healthcare spending.[17] Diabetes is also one of the chronic diseases
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where the annual rate of increase shows little sign of abating.[58] The increasing
incidence of diabetes has been closely associated with the emergence of the
obesity epidemic in America. Among the reasons for the higher costs associated
with diabetes is that individuals diagnosed with the disease are also placed at an
increased risk for comorbidities such as hypertension, renal failure, retinopathy,
neuropathy, and peripheral vascular disease. Improved glucose control, and
more highly aligned healthcare, have been shown to decrease an individual's risk
for acquiring these comorbidities.[17, 50]
The University of Louisville (Louisville, KY), which self-funds the
healthcare benefits for its employees, began to parse their healthcare spending
into chronic disease categories in 2009. At that time, an initial analysis suggested
that almost 20% of the total health care expenditures were associated with an
enrollee having a diagnosis of diabetes. Faced with this rise in cost and the
significant morbidity and mortality that are associated with the disease, the
University of Louisville (UofL) human resources leadership decided to seek
meaningful solutions centered around diabetes with the stated goals of improving
the health of the diabetic enrollees and decreasing the rate of the annual rise in
the healthcare costs associated with this population.
While telephonic based programs have traditionally been used in the care
of patients and enrollees with chronic conditions such as hypertension, diabetes,
hyperlipidemia, and depression, the results have been generally modest.[59]
UofL decided, however, to initiate a pharmacist-led program of medication
therapy management (MTM) in a high-touch environment, based on the Asheville
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Project.[50] This program, created in 1996 by the City of Asheville, North
Carolina used a pharmacist-led intervention program to help it control the rising
healthcare costs it faced as a self-insured employer. This manuscript reports the
initial results of a high-touch, pharmacist-led program, diabetes centered disease
management program at the University of Louisville.

Methods
In January 2010, a healthcare claims analysis of the employees enrolled
in the University of Louisville's health benefit plan suggested the presence of 424
diabetics. All healthcare claims analyzed and identification of members with
diabetes was performed by a separate legal entity using a Business Associate
Agreement. Raw claims data were collected through the University of Louisville's
benefit consultant, Aon Corporation ™ and data analytics were provided by Verisk
Analytics®. Members were determined to have diabetes if they had two or more
outpatient claims with diagnosis of diabetes or one inpatient claim with a
diagnosis of diabetes from January 2009 to December 2009. Once the database
was created, a Paretto curve was created were enrollees were stratified
according to amount (dollars) of claims paid in the plan year. Beginning in March
2010, 120 individuals with the highest insurance claims were initially recruited for
enrollment; later the Diabetes Disease Management Program (DDMP) became
available to all UofL Healthcare members diagnosed with type I or II diabetes.
Notification of eligibility and recruitment were done with direct mailings and
informative luncheons.
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To participate, the enrollees met one-on-one with the designated
pharmacist for an initial visit and signed a "contract" indicating their willingness to
meet regularly with a pharmacist and the understanding that they must remain
active in the program in order to continue to receive the benefit incentives. As a
part of the DDMP, all enrollees were required to meet with a diabetic educator for
two hours of diabetic training and to meet with a nutritionist for two hours of diet
counseling. The pharmacists who participated in the UofL DDMP received
additional training in the care of diabetic patients including the American
Association of Diabetes Educators Core Concepts course.

Table 1
Association of American Diabetes Educators Core Concepts Course
Objectives for Providers
1

Pathophysiology, Epidemiology, and Guidelines for Diabetes Care
•

2

Culturally Competent Supportive Care Across Lifespan
•

3

focuses on effective methods of providing information to patients

Self- Management Education
•

5

compassionate and effective communication with patients

Teaching and Learning Skills
•

4

ensures providers have understanding of pathogenesis and clinical
manifestations of diabetes

how to empower patients to manage their diabetes

Program and Business Management
•

skills to efficiently and effectively provide services to patients
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During the initial visit, the pharmacists recorded medical history, current
medications, current primary and specialist physicians, and attempted to discern
the current level of medical and pharmaceutical understanding of the enrollee as
it pertained to diabetes. Systolic and diastolic blood pressure was measured,
height and weight were recorded, and BMI calculated. Laboratory values
consisting of a Lipid Panel, Basic Metabolic Panel (serum electrolytes, blood
glucose, creatinine), and Urinalysis (micro albuminuria) were obtained as well as
a point of care glycosylated hemoglobin (HbA1c). In general, the goal was HbA1c
:::;;7%.
Diabetics with target glucose control (e.g., HbA1c :57%) were scheduled
for follow-up at three-month intervals. However, diabetics with an HbA1c of 7-8%
and >8% were given suggested lifestyle and medication changes and scheduled
for a follow-up visit In two months and one month, respectively. The pharmacist
also performed a foot exam at each visit to check for signs of neuropathy or
vascular disease and checked the patient's vaccination status. Ophthalmology,
endocrinology, vascular surgery, cardiology, podiatry, and dental referrals were
provided if needed. After each visit a letter was sent by the pharmacist to the
patient's primary physician detailing the encounter and any concerns.
To encourage enrollment and as a major incentive for ongoing
participation, enrollees received free diabetes testing supplies (including
glucometers and test strips) and co-payments for hypertensive, cholesterol
lowering, and diabetic medications were waived at the point of sale. Thus,
income should not be a barrier to access for critical medications.
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As of October 2011, 210 enrollees were contracted into the DDMP.
Seventy-seven (77) of the 210 enrollees have been enrolled for a minimum of 12
months and constitute the dataset for this report. The patients' charts were
reviewed under an IRB approved protocol and clinical data including HbA 1c,
blood pressure, and BMI were analyzed.
By measuring the HbA 1c every three months and abiding by other
evidence-based practice guidelines, providers were also helping to reduce the
patient's Care Gap Index (CGI). The CGI is a proprietary measure calculated by
Verisk Analytics® that quantifies a patient's deviations from evidence-based
treatment guidelines. Ultimately, the CGI gives providers a more comprehensive
view of a patient's health status and compliance with recommended treatments.
The data were then analyzed by conducting a two-way ANOVA with multivariate
analysis using SPSS 20.0.0 statistical software.

Results
To date, 77 individuals have been enrolled for at least 12 months. Of
these, 53 were Caucasian, 22 African-American, and 2 Asian. The mean age
was 57 years old. There were 52 females and 25 males. Also, 72 had DM2 and 5
had DM1.
A statistically significant reduction in the HbA1c was observed among the
77 enrollees in this high-touch diabetes management program. After 12 months
of enrollment, the mean HbA1c was reduced from 7.9% ± 0.2% to 6.9% ± 0.1%
(p < 0.001) with a goal HbA1c being 7.0%. Figure 1 shows the average HbA1c
among the 77 enrollees at 0,3,6,9, and 12 months of enrolling in the DDMP.
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Figures 2, 3, and 4 show the changes in systolic blood pressure (SBP), diastolic
blood pressure (DBP), and BMI, respectively at months 0 and 12.

(p < 0.00 1)
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Figure 1. Decrease in the mean HbA1c at the 0,3,6,9, and 12 month visits.
Overall, the mean HbA1c experienced a statistically significant decrease
from 7.9% ± 0.2% to 6.9% ± 0.1%, P < 0.001. Values depicted are mean ±
standard error.
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Figure 2. Decrease in the mean systolic blood pressure (SBP) at the 0 and
12 month visits. Overall, the mean SBP experienced a non-statistically
significant decrease from 140 ± 2 at month 0 to 137 ± 2 at month 12. Values
depicted are mean ± standard error.
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Figure 3. Decrease in the mean diastolic blood pressure (DBP) at the 0 and
12 month visits. Overall, the mean DBP experienced a non-statistically
significant decrease from 75 ± 1 at month 0 to 74 ± 2 at month 12. Values
depicted are mean ± standard error.
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Figure 4. Decrease in the mean basal metabolic index (BMI) at the 0 and 12
month visits. Overall, the mean DBP experienced a non-statistically
significant increase from 35.8 ± .95 at month 0 to 36 ± .95 at month 12.
Values depicted are mean ± standard error.
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Figure 5. Decrease in the mean care gap index (CGI) at the 0 month (preenrollment) and 12 month (post-enrollment) visits. Overall, the mean CGI
experienced a statistically significant increase from 14.2 at month 0 (preenrollment) to 5.6 at month 12 (post-enrollment). N = 77.

Discussion
The purpose of this study was to determine if a pharmacist-led DDMP
would be successful at improving the health of enrollees diagnosed with
diabetes. As such, the primary variables analyzed for this study were HbA 1c,
SBP, DBP, BMI, and CGI. The primary finding of this study was a significant
improvement in blood glucose control and increased compliance; however, there
was no significant improvement in SBP, DBP, or BMI.
Currently, American Diabetes Association (ADA) recommendations are
that patients maintain their HbA1c :::;7%.[5] Despite the fact that all the enrollees
were being seen by a primary care physician, their average HbA 1c upon
enrollment was 7.9%. Reasons for elevated HbA1c levels included medication
noncompliance, gaps in knowledge of diet and medication, improper diet,
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infrequent blood glucose testing, and poor physician follow-up. Improvement of
the enrollee's HbA 1c was seen within the first three months of enrollment and
was maintained throughout the 12-month period. In addition to meeting with the
diabetes educator and nutritionist near the time of enrollment, the initial
pharmacist visit was also effective at identifying and resolving issues that led to
the increased HbA 1c in a timely manner. At each meeting with the pharmacist,
individual factors that could have led to an elevated HbA 1c were discussed with
the enrollee and individual treatment goals were set. If needed, the pharmacist
provided recommendations to the enrollee's primary care physician as to any
medication changes that would improve the patient's blood glucose control.
As stated, the CGI is a proprietary measure by Verisk Analytics® that
utilizes each enrollee's medical claims data to quantify their deviations from
evidence-based diabetes treatment guidelines. For the DDMP, the pharmacist
tried to ensure that enrollees were achieving clinical guidelines established by
the ADA and other professional organizations. For instance, the pharmacist
ensured that patients were receiving annual physical exams, being seen
regularly by a podiatrist, remained up to date on all of their vaccinations, and
received annual retinal exams. By coordinating among various providers, the
pharmacist made sure that enrollees were compliant with all recommended
clinical guidelines for the treatment of diabetes. In addition, the pharmacist was
also able to review the patient's prescription medication lists and minimize
chances of a patient suffering from an adverse drug event (ADE). This attention
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to detail is reflected in the decrease of the average CGI from 14.2 to 5.2 over the
12-month enrollment.
Also, Figure 5 demonstrates that patients with the highest care gaps at
enrollment enjoyed some of the largest reductions in CGI thanks to pharmacist
adherence to best practice guidelines. Though the way in which the CGI is
calculated changes with alterations in recommended guidelines of best practice,
it does provide us with an indication of how successful the DDMP has been in
increasing the enrollee's treatment compliance.
Collaboration among the various stakeholders involved was essential to
ensuring that our DDMP achieved the desired clinical outcome. Specialist
physicians at UofL such as nephrologists, podiatrists, and ophthalmologists were
recruited to become involved in the DDMP and to provide care for patients with
possible diabetic complications. To facilitate participation in the program,
administrators met with each specialist physician and asked them to provide
clinical criteria that the pharmacist could use in determining whether a referral to
their clinic was appropriate. Allowing the various providers an opportunity to have
input into the design of the program and to determine how their specialty would
be represented helped to ensure that each specialist's clinical boundaries were
respected and allowed us to maintain support for the DDMP.
Enrollees were also provided incentives to remain engaged in the DDMP,
which created more interest and participation than would have otherwise been
expected. Effective provision of disease management services requires
longitudinal care and it is essential that enrollees continue to feel the benefits of
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the program so that they remain actively involved. Providing incentives helped
ensure that the patients remained in the DDMP even after their HbA 1c was at
goal. Follow-up appointments with the pharmacist were scheduled so as to
coincide with the date of the patient's next medication refill in order to make
ongoing participation as convenient as possible. In addition, we helped to assure
continuity of care for the enrollees by only employing a handful of pharmacists to
provide clinical services. By maintaining a high retention of enrollees, we helped
to ensure that their clinical progress was being maintained and that any deficits in
their care were handled in a timely manner.
As third-party payers are increasingly looking for proven methods to
reduce healthcare costs, the utilization of pharmacists as mid-level providers of
MTM services will increase. There have been numerous pharmacist-led diabetes
interventions introduced by third-party payers acrosS the country with similar
success in improving the patient's diabetes disease management.[24, 50] In fact,
Medicare requires providers of its Part 0 prescription drug plan to offer MTM
services to patients who take five or more medications and whose prescription
drug costs exceed a certain threshold.[28, 37, 38] Given the increasing burden
that prescription medication costs place on third-party payers, pharmacists'
expertise in pharmacotherapy will be increasingly called upon to optimize
medication therapy and to minimize errors and duplications in treatment.
The UofL DDMP demonstrated that a high-touch intervention led by
pharmacists can be successful at improving clinical outcomes and adherence to
treatment guidelines for patients diagnosed with diabetes. This collaborative
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method of healthcare delivery could be duplicated and adapted to provide
improved clinical outcomes related to other chronic diseases as well.
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CHAPTER 4
SUMMARY

As healthcare costs continue to grow at an unacceptable rate and
physicians are increasingly pressured to manage complex patients in a limited
amount of time, the need for pharmacist provision of MTM services will grow as
well. This thesis demonstrated the utility of a high-touch, pharmacist-led diabetes
disease management program in achieving recommended clinical outcomes for
patients with diabetes. The significant reduction in HbA 1c was achieved after an
average three months of enrollment and sustained throughout the duration of the
DDMP. Moreover, the pharmacist-led DDMP was significant in that it successfully
reduced the average CGI of patients enrolled in the DDMP for 12 months. By
increasing the patient's adherence to evidence-based guidelines, it is hoped that
our patient population would experience decreased complications and associated
healthcare expenditures over the long term.
Future studies could focus on expansion of the DDMP to include
implementation of a hypertension focused intervention. Additionally, the DDMP
could implement interventions focused on other common comorbidities among
diabetics such as hyperlipidemia. Successful pharmacist-led hypertension and
hyperlipidemia interventions were successfully implemented in the Asheville
Project.[60] Given that these conditions are highly prevalent among diabetics, a
substantial reduction in morbidity and mortality could be achieved by ensuring
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that patients enrolled in the DDMP are adhering to evidence-based guidelines in
these areas. Further, pharmacist interventions could be designed for other
chronic conditions with high rates of polypharmacy such as congestive heart
failure and COPD.
As the demand for healthcare continues to rise, the pharmacist provision
of MTM services will continue to grow in popularity as third-party payers seek to
ensure the efficient and effective use of costly medications. Patients will also
benefit tremendously from the reduced morbidity and mortality that result from
stricter adherence to evidence-based clinical guidelines for diseases such as
diabetes. Pharmacist provision of MTM services will be essential to providing
comprehensive healthcare as the number of patients requiring complex
medication therapy continues to grow.
Future studies could focus on expansion of the DDMP to include
implementation of a hypertension or BMI focused intervention, similar to the
Asheville Project.
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